About AZI
AZI is a Healthcare company based in Bunker Hill (United States) founded in 2017 by Gregory W Brooksby and Clyde Jupiter. Radiopharmaceuticals for diagnostic imaging are developed and produced. AZI has raised $58.33 million across 1 funding round. Its chief executive, as recorded, is Gregory W Brooksby. AZI offers products and services including Medical Isotopes. Its focus areas include Life Sciences, Imaging Diagnostics, Accessories and Radioisotopes. Its legal entity is Arizona Isotopes Science Research Corp. Its competitors include ImaginAb, NorthStar Medical Radioisotopes and NuView Life Sciences; 3 of its 3 listed competitors have raised funding.
Company details
AZI was founded in 2017 and is based in Bunker Hill, United States. Operations focus on the development and production of radiopharmaceuticals within the medical imaging sector. A range of isotopes, including Strontium-82, Germanium-68, Iodine-123, and Actinium-225, is manufactured for diagnostic imaging and therapeutic applications. The portfolio supports clinical uses in nuclear medicine.
- Headquarters Bunker Hill, United States
- Founders Gregory W Brooksby, Clyde Jupiter
- SectorsHealthcare
- Phone•••• ••••
- Website azisotopes.org
- Social LinkedIn Facebook Instagram
- Legal Name Arizona Isotopes Science Research Corp.
- Total Equity Funding$58.33M (USD)
in 1 rounds
- Latest Funding Round$58.33M (USD), Series C
May 2018
Products & Services of AZI
AZI offers a comprehensive portfolio of products and services, including Medical Isotopes.
Products for developing and producing isotopes in nuclear medicine
Funding Insights of AZI
AZI has successfully raised a total of $58.33M through 1 strategic funding round. The most recent funding activity was a Series C round of $58.33 million completed in May 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $58.33M
- Total Rounds 1
- Last Round Series C — $58.33M
- First Round $58.33M
(May 2018)
All 1 funding rounds of AZI with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2018 | $58.33M | Series C | – | – | – |
People of AZI
2 people are tracked at AZI (2 in leadership).
| Name | Role | Group |
|---|---|---|
Gregory W Brooksby | Co-Founder & CEO | Leadership |
Clyde Jupiter | Co-Founder | Leadership |
Complete people profiles for AZI
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of AZI
2 dated milestones of AZI across 1 years, from founding to its latest funding, stage changes and deals.
- Founded AZI is founded.
- Funding First funding round of $58.3M.
Competitors of AZI
AZI has 3 listed competitors in our database, 3 of them funded. They include ImaginAb, NorthStar Medical Radioisotopes and NuView Life Sciences.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| imaginab.com | 2007 | Los Angeles, United States | $59.64M | 17 | ImaginAb is focused on developing advanced immuno-oncology imaging technologies. | |
| northstarnm.com | 2006 | Madison, United States | $15.09M | Provider of sourcing, purification, and separation technologies for the Nuclear Medicine market | ||
| nuviewlifesciences.com | 2005 | Park, United States | $90M | Cancer diagnosis devices targeting VPAC1 receptors are developed. |
Detailed competitors of AZI
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Imaging Diagnostics
3 companies that operate in the same segment as AZI (Imaging Diagnostics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Handheld ultrasound devices are developed for whole-body medical imaging. | 2011 | Guilford, Connecticut, United States | USD 350 M | USD 97.61 M | 464 | |
Robotic microsurgical systems for endoscopy are developed. | 2007 | Redwood City, California, United States | USD 733.62 M | 91 | ||
Ultrasound images are analyzed via AI-based software provided by Exo. | 2015 | Redwood City, California, United States | USD 463.39 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about AZI
AZI was founded in 2017 and raised its 1st funding round 1 year after it was founded.
AZI is headquartered in Bunker Hill, United States. It is registered at Bunker Hill, Illinois, United States.
Gregory W Brooksby is the CEO of AZI, as recorded in our data. They have also founded this company.
AZI is a funded company, having raised a total of $58.33M across 1 funding round to date. The company's 1st funding round was a Series C of $58.33M, raised on May 2018.
AZI was founded in 2017 and is based in Bunker Hill, United States. Operations focus on the development and production of radiopharmaceuticals within the medical imaging sector. A range of isotopes, including Strontium-82, Germanium-68, Iodine-123, and Actinium-225, is manufactured for diagnostic imaging and therapeutic applications. The portfolio supports clinical uses in nuclear medicine.
AZI's top competitors include ImaginAb, NorthStar Medical Radioisotopes and NuView Life Sciences.
AZI offers Medical Isotopes.
AZI operates through Arizona Isotopes Science Research Corp..